Mabtas 100 (Rituximab Vials) 100mg

Mabtas 100 contains rituximab, a monoclonal antibody used to treat certain autoimmune conditions and cancers. This vial formulation at 100mg strength is stored between 2-8°C. Rituximab works by targeting specific cells in the immune system.

Strength

100mg

Pack Size

1's

Storage

2-8°

Manufacturer / TM Owner

Intas Pharmaceuticals Ltd

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Rituximab is commonly used to manage autoimmune disorders like rheumatoid arthritis when other treatments are ineffective. It is also prescribed for certain blood cancers such as non-Hodgkin lymphoma and chronic lymphocytic leukemia. Patients often ask, 'what is rituximab used for' to understand its role in immune system modulation and cancer therapy.

Side Effects

Rituximab helps reduce symptoms associated with autoimmune diseases by targeting B-cells, which play a role in inflammation. For cancer patients, it works by binding to cancerous B-cells to help the immune system recognize and destroy them. Common effects include temporary reductions in certain immune cells during treatment.

Precautions & Warnings

Mabtas 100 should be handled with care and stored refrigerated between 2-8°C. Avoid exposure to extreme temperatures or direct sunlight. Patients should inform their healthcare provider about any ongoing infections or recent vaccinations before starting treatment.

Avoid Interactions

Rituximab may interact with other medications that affect the immune system, such as immunosuppressants or live vaccines. Combining it with certain chemotherapy drugs or other monoclonal antibodies could alter effectiveness or increase side effects. Always disclose all medications to your healthcare provider.

References

Frequently Asked Questions

Rituximab is used to treat autoimmune diseases like rheumatoid arthritis and certain blood cancers such as non-Hodgkin lymphoma.

Mabtas 100 is administered by a healthcare professional via intravenous infusion in a clinical setting.

Common side effects may include infusion reactions, infections, or temporary decreases in certain blood cells.

No, Mabtas 100 should be stored refrigerated between 2-8°C and protected from light.

Consult a healthcare provider; rituximab may pose risks during pregnancy and should only be used if clearly needed.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.